Aspirin as secondary prevention in colorectal cancer liver metastasis (ASAC trial) : study protocol for a multicentre randomized placebo-controlled trial

Colorectal cancer is one the most common cancers in the western world with increasing incidence. Approximately 50% of the patients develop liver metastases. Resection of liver metastases is the treatment of choice although almost half of the resected patients get recurrence in the liver.
Funding agencies: The Research Council of Norway (Project#:235340); The Norwegian Cancer Society (Project# 182788); and KLINBEFORSK (Project#; 2016201). The funding body is not involved in study design, collection or interpretation of data nor in publication/writing of study results.The ASAC study group: Kristoffer W. Brudvik, Åsmund A. Fretland, Arild Horn, Dyre Kleive, Knut J. Labori, Kristoffer Lassen, Bård I. Røsok, Jon A. Søreide, Tore Tholfsen, Olaug Villanger & Anne Waage